High tumor load in the blood (CD4/CD8 ≥ 10; CD4+CD7- ≥ 40%; CD4+CD26- ≥ 30%; ≥ 1000/μL of CD4+CD26- or CD4+CD7- cells or other aberrant population of lymphocytes identified by flow cytometry). This evidence concerns the gene CD4 and neoplasm.